(-0.46%) 5 048.42 points
(-0.98%) 38 086 points
(-0.64%) 15 612 points
(0.24%) $83.77
(-2.26%) $1.601
(0.11%) $2 345.10
(0.41%) $27.47
(0.73%) $927.20
(-0.26%) $0.932
(-0.25%) $10.96
(-0.39%) $0.799
(-0.17%) $92.17
@ $19.52
Utstedt: 14 feb 2024 @ 20:28
Avkastning: -19.34%
Forrige signal: feb 14 - 17:53
Forrige signal:
Avkastning: 2.55 %
Live Chart Being Loaded With Signals
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong...
Stats | |
---|---|
Dagens volum | 515 424 |
Gjennomsnittsvolum | 645 011 |
Markedsverdi | 1.55B |
EPS | $0 ( 2024-02-27 ) |
Neste inntjeningsdato | ( $-0.930 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.50 |
ATR14 | $0.0210 (0.13%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-03 | Smiley Joshua L | Buy | 7 145 | American Depositary Shares |
2024-04-04 | Smiley Joshua L | Sell | 1 988 | American Depositary Shares |
2024-04-03 | Smiley Joshua L | Sell | 7 145 | Restricted Share Units |
2024-04-03 | Reinhart Harald | Buy | 5 270 | American Depositary Shares |
2024-04-04 | Reinhart Harald | Sell | 2 105 | American Depositary Shares |
INSIDER POWER |
---|
72.37 |
Last 100 transactions |
Buy: 2 027 943 | Sell: 363 897 |
Volum Korrelasjon
Zai Lab Ltd Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
MMAC | 0.88 |
NETE | 0.872 |
BOCH | 0.84 |
TFSL | 0.832 |
SHSP | 0.828 |
SNFCA | 0.824 |
LWAC | 0.815 |
DOOO | 0.809 |
CLGN | 0.804 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Zai Lab Ltd Korrelasjon - Valuta/Råvare
Zai Lab Ltd Økonomi
Annual | 2023 |
Omsetning: | $266.72M |
Bruttogevinst: | $170.90M (64.08 %) |
EPS: | $-3.46 |
Q4 | 2023 |
Omsetning: | $65.83M |
Bruttogevinst: | $40.59M (61.66 %) |
EPS: | $-0.980 |
Q3 | 2023 |
Omsetning: | $69.23M |
Bruttogevinst: | $43.75M (63.20 %) |
EPS: | $-0.710 |
Q2 | 2023 |
Omsetning: | $68.86M |
Bruttogevinst: | $45.10M (65.49 %) |
EPS: | $-1.250 |
Financial Reports:
No articles found.
Zai Lab Ltd
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.